← ProQR Therapeutics N.V. (PRQR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ProQR Therapeutics N.V. (PRQR)
Pharmaceutical Preparations · market cap $185M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
ProQR Therapeutics N.V. (NASDAQ: PRQR) is a Dutch RNA-editing biotech based in Leiden, Netherlands, with ~150 employees and a ~$198M market cap at ~$1.73/share. The company's lead asset, sepofarsen, is in Phase 3 for Leber Congenital Amaurosis 10 (LCA10), a rare inherited retinal dystrophy, while three additional programs (QR-1123, QR-421a, QR-010) are in Phase 2 across other rare genetic diseases. The next disclosed catalyst is an August 6, 2026 earnings release.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| QR-1123 | Phase 2 | Autosomal Dominant Retinitis Pigmentosa |
| QR-421a | Phase 2 | Retinitis Pigmentosa |
| QR-010 | Phase 2 | Cystic Fibrosis |
| sepofarsen | Phase 3 | Leber Congenital Amaurosis 10 |
Price & technical context
3-month
-9.9%
6-month
-4.7%
12-month
-23.5%
52-wk range
$1.37–$3.05
vs 50-day MA
-15.7%
vs 200-day MA
-7.1%
Realized vol
75.8%
Max drawdown
-75.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PRQR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.